Male Infertility - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 42 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Male Infertility - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Male Infertility - Pipeline Review, H2 2014', provides an overview of the Male Infertility's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Male Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Male Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Male Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Male Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Male Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Male Infertility Overview 6
Therapeutics Development 7
Pipeline Products for Male Infertility - Overview 7
Pipeline Products for Male Infertility - Comparative Analysis 8
Male Infertility - Therapeutics under Development by Companies 9
Male Infertility - Therapeutics under Investigation by Universities/Institutes 10
Male Infertility - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Male Infertility - Products under Development by Companies 13
Male Infertility - Products under Investigation by Universities/Institutes 14
Male Infertility - Companies Involved in Therapeutics Development 15
Pantarhei Bioscience BV 15
PharmaEssentia Corporation 16
PlasmaTech Biopharmaceuticals, Inc. 17
Zydus Cadila Healthcare Limited 18
Male Infertility - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 26
Drug Profiles 28
(oxytocin + estrogen) - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Biosimilar 4 for Acute Myocardial Infarction and Infertility - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Biosimilar 5 for Infertility - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Biosimilar 6 for Infertility - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Biosimilar 7 for Infertility and Oncology - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MCS-5 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Oral Fertility Drugs - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PEG-FSH - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Agonize FSHR for Infertility - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecules for Male Infertility - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Stem Cell Therapy for Male Infertility - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Male Infertility - Recent Pipeline Updates 39
Male Infertility - Dormant Projects 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products under Development for Male Infertility, H2 2014 7
Number of Products under Development for Male Infertility - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Male Infertility - Pipeline by Pantarhei Bioscience BV, H2 2014 15
Male Infertility - Pipeline by PharmaEssentia Corporation, H2 2014 16
Male Infertility - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H2 2014 17
Male Infertility - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Assessment by Combination Products, H2 2014 20
Number of Products by Stage and Target, H2 2014 22
Number of Products by Stage and Mechanism of Action, H2 2014 24
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Male Infertility Therapeutics - Recent Pipeline Updates, H2 2014 39
Male Infertility - Dormant Projects, H2 2014 40